The novel calcium sensitizer levosimendan activates the ATP-sensitive K+ channel in rat ventricular cells

Journal of Pharmacology and Experimental Therapeutics

Volumn 283, Issue 1, 1997, Pages 375-383

  Yokoshiki, Hisashi ^a   Katsube, Yasuhiro ^a   Sunagawa, Masanori ^a   Spereulkis, Nicholas ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATE; GLIBENCLAMIDE; LEVOSIMENDAN; POTASSIUM CHANNEL; PYROPHOSPHATE;

ACTION POTENTIAL; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CORONARY ARTERY DILATATION; ELECTROPHYSIOLOGY; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART VENTRICLE; HUMAN; INOTROPISM; PATCH CLAMP; POTASSIUM CURRENT; PRIORITY JOURNAL; RAT;

ACTION POTENTIALS; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ANIMALS; CALCIUM; CALCIUM CHANNELS; CARDIOTONIC AGENTS; HEART; HEART VENTRICLES; HYDRAZONES; POTASSIUM CHANNELS; PYRIDAZINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0030771922     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. BODE, D. C., KANTKR, J. R. AND BRUNTON, L. L.: Cellular distribution of phosphodiesterase isoforms in rat cardiac tissue. Circ. Res. 68: 1070-1079, 1991.
2. BOKNIK, P., NEUMANN, J., KASPAREIT, G., SCHMITZ, W., SCHOLZ, H., VAHLENSlKCK, U. AND ZIMMERMANN, N.: Mechanisms of the contractile effects of levosimendan in the mammalian heart. J. Pharmacol. Exp. Ther. 280: 277-283, 1997.
3. 2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ. Res. 77:107-113, 1995.
4. HAIKALA, H., KAIVOLA, J., NISSINKN, E., WALL, P., LEVIJOKI, J. AND LINDEN, I-B.: Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan J. Mol. Cell. Cardiol. 27: 1859-1866, 1995a.
5. KAIKALA, H., NISSINKN, E., ETKMADZADEH, E., LEVIJOKI, J. AND LINDEN, I-B.: Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. J. Cardiovasc. Pharmacol. 25: 794-801, 1995b.
6. HARKIN, C. P., PAGEL, P. S., TESSMER, J. P. AND WARLTIER, D. C.: Systemic and coronary hemodynamic actions and left ventricular functional effects of levosimendan in conscious dogs. J. Cardiovasc. Pharmacol. 26: 179-188, 1995.
7. HEARSE, D. J.: Activation of ATP-sensitive potassium channels: a novel pharmacological approach to myocardial protection? Cardiovasc. Res. 30: 1-17, 1995.
8. HENRY, P., ESCANDE, D.: Do potassium channel openers compete with ATP to activate ATP sensitive potassium channels? Cardiovasc. Res. 28: 754-759, 1994.
9. IRISAWA, H. AND KOKUBUN, S.: Modulation by intracellular ATP and cyclic AMP of the slow inward current in isolated single ventricular cells of the guineapig. J. Physiol. (Lond.) 338: 321-337, 1983.
10. JAHANGIR, A., TERZIC, A. AND KURACHI, Y.: Intracellular acidification and ADP enhance nicorandil induction of ATP sensitive potassium channel current in cardiomyocytes. Cardiovasc. Res. 28: 831-835, 1994.
11. JANSE, M. J AND WIT, A. L.: Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction. Physiol. Rev. 69: 1049-1169, 1989.
12. KAKEI, M., NOMA, A. AND SHIBASAKI, T.: Properties of adenosine-triphosphate-regulated potassium channels in guinea-pig ventricular cells. J. Physiol. (Lond.) 363: 441-462, 1985.
13. KASZALA, K., VEGH, A., UDVARY, E. AND PAPP, J. G.: Is levosimendan antiarrhythmic or arrhythmogenic? (Abstract) J. Mol. Cell. Cardiol. 26: LXXXIII, 1994.
14. KELSO, E. J., MCDERMOTT, B. J. AND SILKE, B.: Cardiotonic actions of selective phosphodifsterase inhibitors in rat isolated ventricular cardiomyocytes. Br. J. Pharmacol. 110: 1387-1394, 1993.
15. ATP, channel by ADP and diazoxide requires nucleotide hydrolysis in mouse pancreatic β-cells. J. Physiol. (Lond.) 463: 349-365, 1993.
16. LILLEBERG, J., SUNDBKRG, S. AND NIEMINEN, M. S.: Dose-range study of a new calcium sensitizer, levosimendan, in patients with left ventricular dysfunction. J. Cardiovasc. Pharmacol. 26 (Suppl. 1): S63-S69, 1995.
17. NAKAYAMA. K., FAX, Z., MARUMO, F. AND HIRAOKA, M.: Interrelation between puiacidil and intracellular ATP concentrations on activation of the ATP-sensitive K current in guinea pig ventricular myocytes. Circ. Res. 67: 1124-1133, 1990.
18. NIELSEN-KUDSK, J. E. AND ALDERSHVILE, J.: Will calcium sensitizers play a role in the treatment of heart failure? J. Cardiovasc. Pharmacol. 26 (Suppl. 1) S77-S84, 1995.
19. OHYA, Y. AND SPERELAKIS, N.: Modulation of single slow (L-typel) calcium channels by intracellular ATP in vascular smooth muscle cells. Pflugers. Arch. 414: 257-264, 1989.
20. O'ROURKE, B., BACKX, P. H. AND MARBAN, E.: Phosphorylation-independent modulation of L-type calcium channels by magnesium-nucleotide complexes. Science 257: 245-248, 1992.
21. PACKER, M.: Vasodilator and inotropic drugs for the treatment of chronic heart failure: distinguishing hype from hope. J. Am. Coll. Cardiol. 12: 1299-1317, 1988.
22. PACKER, M., CARVER, J. R., RODEHEFFER, R. J., IVANHOE, R. J., DIBIANCO, R., ZELDIS, S. M., HENDRIX, G. H., BOMMER, W. J., ELKAYAM, U., KUKIN, M. L., MALLIS, G. I., SOLLANO, J. A., SHANNON, J., TANDON, P. K. AND DEMETS, D. L. FOR THE PROMISE STUDY RESEARCH GROUP: Effect of oral milrinone on mortality in severe chronic heart failure. N. Engl. J. Med. 325: 1468-1475, 1991.
23. PAGEL, P. S., HARKIN, C. P., HETTRICK, D. A. AND WARLTIER, D. C.: Zatebradine, a specific bradycardic agent, alters the hemodynamic and left ventricular mechanical actions of levosimendan, a new myofilament calcium sensitizer, in conscious dogs. J. Pharmacol. Exp. Ther. 275: 127-135, 1995.
24. 2+ sensitizer, levosimendan, to recombinant human cardiac troponic C. J. Biol. Chem. 269: 28584-28590, 1994.
25. POLSON, J. B.: Cyclic nucleotide phosphodiesterases and vascular smooth muscle. Annu. Rev. Pharmacol. Toxicol. 36: 403-427, 1996.
26. + channel activity and contractile behavior in mammalian ventricle by the potassium channel openers cromakalim and RP49356. J. Pharmacol. Exp. Ther. 255: 429-435, 1990.
27. RUMP, A. F. E., ACAR, D. AND KLAUS, W.: A quantitative comparison of functional and anti-ischaemic effects of the phosphodiesterase-inhibitors, amrinone, milrinone and levosimendan in rabbit isolated hearts. Br. J. Pharmacol. 112: 757-762, 1994a.
28. RUMP, A. F. E., ACAR, D., ROSEN, R. AND KLAUS, W.: Functional and antiischemic effects of the phosphodiesterase inhibitor levosimendan in isolated rabbit hearts. Pharmacol. Toxicol. 74: 244-248, 1994b.
29. SANDELL, E.-P., HAYHA, M., ANTILA, S., HEIKKINEN, P., OTTOILA, P., LEHTONEN, L. A. AND PENTIKAINEN, P. J.: Pharmacokinetics of levosimendan in healthy volunteers and patients with congestive heart failure. J. Cardiovasc. Pharmacol. 26 (Suppl. 1): S57-S62, 1995.
30. + channel: a comparison with pinacidil and lemakalim. Circ. Res. 69: 1152-1158, 1991.
31. SPERELAKIS, N.: Basis of the cardiac resting potential. In: Physiology and Pathology of the Heart, 3rd ed., ed. by N. Sperelakis, Chap. 3, pp. 55-76, Kluwer Academic Publishers, Norwell, MA, 1995.
32. SPERELAKIS, N. AND SCHNEIDER, J. A.: A metabolic control mechanism for calcium ion influx that may protect the ventricular myocardial cell. Am. J. Cardiol. 37: 1079-1085, 1976.
33. STOSSEL, T. P.: On the crawling of animal cells. Science 260: 1086-1094, 1993.
34. SUNDBERG, S., LILLEBERG, J., NIEMINEN, M. S. AND LEHTONEN, L.: Hemodynamic and neurohumoral effects of levosimendan, a new calcium sensitizer, at rest and during exercise in healthy men. Am. J. Cardiol. 75: 1061-1066, 1995.
35. + channel-opening drugs. Am. J. Physiol. 269 (Cell Physiol. 38: C525-C545, 1995.
36. + channel-opening drugs. Am. J. Physiol. 269 (Cell Physiol. 38: C525-C545, 1995.
37. THE CONSENSUS TRIAL STCDY GHOUP: Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N. Engl. J. Med. 316: 1429-1435, 1987.
38. THE SOLVD INVESTIGATORS: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 325: 293-302, 1991.
39. THURINGER, D. AND ESCANDE, D.: Apparent competition between ATP and the potassium channel opener RP 49356 on ATP-sensitive K channels of cardiac myocytes. Mol. Pharmacol. 36: 897-902, 1989.
40. + channel in ventricular cell of guinea-pig. J. Physiol. (Lond.) 437: 239-256, 1991.
41. VEGH, A., PAPP, J. G., UDVARY, E. AND KASZALA, K.: Hemodynamic effects of calcium-sensitizing agents. J. Cardiovasc. Pharmacol. 26 (Suppl. 1): S20-S31, 1995.
42. VIRAG, L., HALA, O., MARTON, A., VARRO, A. AND PAPP, J. G.: Cardiac electrophysiological effects of levosimendan, a new calcium sensitizer. Gen. Pharmacol. 27: 551-556, 1996.
43. 2+ channel currents by intracellular ATP in smooth muscle cells of rat mesenteric artery. Am. J. Physiol. 272 (Heart Circ. Physiol. 41): H814-H819, 1997.
44. 2+ channel currents by intracellular ATP in smooth muscle cells of rat mesenteric artery. Am. J. Physiol. 272 (Heart Circ. Physiol. 41): H814-H819, 1997.
45. YOKOSHIKI, H., SUMII, K. AND SPERELAKIS, N.: Inhibition of L-type calcium current in rat ventricular cells by the tyrosine kinase inhibitor, genistein and its inactive analog, daidzein. J. Mol. Cell. Cardiol. 28: 807-814, 1996.